Company ProfilePremium

Jatcorp Limited

Company Profile Analysis

Ticker: JAT.AX

ESOMAR 23 Corporate BadgeISO Certifications Badge
Jatcorp Limited - Company showcase

Year Founded & Workforce

2006

Jatcorp Limited logo

Jatcorp Limited Employee Contacts

We don't hold contact details for this company yet — you can request them.

Request Employee Contacts

Jatcorp Limited Overview

Jatcorp is a micro-cap Australian health-and-wellness dairy nutrition company whose identity rests on two assets. The first is a portfolio of lactoferrin-fortified formulated milk powders sold under the Neurio® and Moroka® brands, aimed mainly at Chinese consumers seeking immunity products. The second is the ANMA powder-blending and canning facility in Derrimut, Melbourne, which supports both its own brands and higher-margin OEM contract manufacturing for third parties. In FY2026 it generated A$38.9m revenue (+23%), a A$6.1m audited gross profit and a A$4.7m statutory net loss. Its auditor has flagged a going-concern material uncertainty. Roughly three-quarters of revenue is booked in its Australian segment, much of it with a single customer and likely destined for Chinese cross-border channels. Its largest shareholder (31.3%) is also its exclusive China distributor. The equity story is a turnaround: shrinking the cost base, rebuilding Neurio after a Chinese trademark loss, and growing OEM and Southeast Asian revenue.


Company's own description (paraphrased from 1H FY26 Interim Report, Directors' Report "Principal activities")

The company describes itself as an innovation-led producer of dairy and nutrient products in Australia serving Asia-Pacific markets. Its activities fall into two strands.

The first strand is innovation and new product development. This means manufacturing a range of consumer formulations for every age group from infants to seniors. The formulations frequently incorporate lactoferrin, which the company positions as supporting immune function, intestinal health and related benefits.

The second strand is brand development. This centres on the flagship brands Neurio® and Moroka®. It covers marketing and promotion and the sale of both proprietary and client products. Distribution is multi-channel, spanning traditional retail and e-commerce, with Australia and China as the primary markets.

In ASX boilerplate, the company calls itself a leading producer of supplementary food and plant-based products (CEO appointment announcement, 15 September 2025).

Independent characterisation

Jatcorp is best understood as a small vertically integrated nutritional-powder brand owner and contract manufacturer whose end-demand is overwhelmingly Chinese. It does not farm milk or produce lactoferrin; it buys dairy bases and functional ingredients, then blends, cans and packs them at ANMA. It sells its own brands to distributors and e-commerce operators, and sells manufacturing capacity to other brand owners on an OEM basis.

Value-chain position

  • Upstream: purchased milk powders, lactoferrin, IgG, vitamins and minerals, and packaging (raw materials A$2.22m and packaging A$1.19m of inventory at 30 June 2026).

  • Midstream: blending and canning at ANMA.

  • Downstream: sale to distributors and cross-border e-commerce (CBEC) operators, principally the HS Group (HS Global E-Commerce (HK) Limited / "H&S International"), plus Australian, New Zealand, Hong Kong and Vietnamese channels.

Revenue model

  • 100% of FY2026 revenue is "goods transferred at a point in time" (FY2026 Preliminary Financial Report, Note 4). There is no subscription, licensing or service revenue line.

  • The mix splits between own-brand product sales (Neurio, Moroka, Jinvigorate and others) and OEM manufacturing revenue (e.g., BTNature, a Taiwan client, and the new India-bound customer).

  • The precise branded-versus-OEM split is not publicly disclosed.

Commercial structure worth noting

  • Large customer prepayments (contract liabilities of A$4.22m at 30 June 2026). Customers paid A$18.94m in advance during FY2026 (Note 10).

  • A trade promotion expense (TPE) payable to the HS distributor as a fixed percentage of sales. From FY2026 this is netted against revenue (Note 2).

  • A share-based sales incentive plan with a distributor (1,000,000 shares issued 2 September 2025).

Customer types

  • Distributors and wholesale partners (largest category). One Australian-segment customer contributed A$23.64m (60.8%) of FY2026 revenue, and one China-segment customer A$5.03m (12.9%) (Note 3, Major customers).

  • E-commerce platforms. Historic flagship stores on Tmall Global, JD Worldwide/JD Global and Pinduoduo were operated before the company terminated its own China online store operations in Q4 FY2026 (Kalkine summary of Q4 FY26 4C).

  • Bricks-and-mortar mother-and-baby stores in China (Moroka in approximately 150 stores, 1H FY26), plus stores in Hong Kong and Vietnam.

  • OEM brand-owner customers using ANMA capacity.

End-markets served

  • Paediatric and maternal nutrition (formulated milk powders for children).

  • Adult and senior immunity and wellness powders.

  • Medical-adjacent nutrition (Jinvigorate Diabetic Formula, low-GI certified).

  • OEM nutritional powders for third-party brands.

Strategy

Stated strategy themes (latest filings; paraphrased)

  1. Brand-led growth with OEM support. In 2024 management announced a pivot away from a distribution and OEM model towards its own brands, with OEM manufacturing taking a supporting role (FoodNavigator-Asia, Sept 2024). By FY2026 the emphasis had rebalanced: management now describes higher-margin OEM manufacturing at ANMA as a key priority alongside Moroka brand expansion (1H FY26 Interim Report outlook).

  2. Dual-brand lactoferrin strategy. A "double-brand strategy" around lactoferrin products (1H FY24 Interim Report), now Neurio plus Moroka.

  3. "New channels" in China. Moving beyond pure e-commerce into mother-and-baby retail (about 150 stores in 1H FY26). This culminated in a new cooperation model with HS as exclusive China distributor and the termination of company-run online stores (Q4 FY26).

  4. Southeast Asian diversification. Vietnam exclusive distributor (signed 1H FY26); Malaysia and Indonesia discussions under way.

  5. Manufacturing capability. Infrastructure upgrades and automation at ANMA; capacity doubled in 1H FY26; next upgrade phase in preparation.

  6. Cost discipline. Every expenditure category fell in Q4 FY26: manufacturing and operating costs −20%, advertising −57%, administration −19% (Q4 FY26 4C).

  7. Inorganic optionality. Management said in 2024 that it was looking for Australian health and nutrition brands to acquire (FoodNavigator-Asia). No transaction has been announced since.

  8. Risk management priorities. Four stated focus areas: protecting trademarks and IP, diversifying the customer base through portfolio expansion, entering new markets, and retaining talent (1H FY26 Interim Report).

Initiatives in the last 24 months (Oct 2024 – Oct 2026)

InitiativeDateDetailTarget / status
H&S International sales incentive deed (Moroka)Feb 2025Incentive arrangement to drive Moroka purchases in mainland ChinaA$11m FY2026 Moroka purchase target. Actual FY2026 China-segment revenue was A$7.97m, though HS purchases may be booked in other segments (not disclosed)
Sales incentive plan share issue2 Sep 20251,000,000 shares issued to a distributor (A$280k at A$0.28 per the interim report; A$442k per the FY2026 accounts, a discrepancy)Completed
HQ consolidation to DerrimutJul 2025Registered office moved to the ANMA siteCompleted
Non-core property saleOct–Nov 2025A$1.10m saleCompleted
Vietnam exclusive distribution agreement1H FY26Products developed specifically for VietnamLaunched; A$0.37m FY2026 revenue
BTNature manufacturing arrangement1H FY26OEM production commencedOngoing
ANMA production line upgrade1H FY26Doubled capacityCompleted; next phase planned
China retail expansion1H FY26Moroka into about 150 mother-and-baby storesOngoing
CIIE Shanghai participationNov 2025Showcased manufacturing; prospective customers then visited ANMACompleted
A$4.2m entitlement offerDec 2025 – Jan 2026Fully underwritten by HS Global E-Commerce (HK)Completed 16 Jan 2026
China distribution model resetQ4 FY26New cooperation model with H&S as exclusive China distributor; termination of company-run online storesUnder execution
India-bound OEM customerQ4 FY26ANMA's first OEM customer selling into IndiaCommenced
Malaysia and Indonesia distributionQ4 FY26Distributor discussions progressingPending
R&DFY2026 outlookTargeted R&D to support innovation in branded and OEM offeringsNo spend disclosed

ESG / sustainability commitments

None disclosed. The company will first become subject to mandatory climate reporting (AASB S2) potentially for the year ending 30 June 2028 (1H FY26 Interim Report).

Medium-term targets and guidance

No quantitative medium-term revenue, margin or EBITDA targets have been issued. The only quantified commercial target located is the A$11m FY2026 Moroka purchase target under the HS deed. The going-concern note refers to a cash-flow forecast "assuming that project profits are met", but the projections are not disclosed.

Products & Services

Jatcorp has no product segments, so products are organised by brand and channel. Pricing is not publicly disclosed for any product.

Own brands — functional dairy (core)

Brand / productOwner entityDescription and key specificationsTarget customerLaunch / latest yearNotes
Neurio® Formulated Milk Powder with LactoferrinSunnya Pty Ltd (51%)Lactoferrin formulated milk powder with sialic acid, zinc, iron and calcium (FoodNavigator-Asia, Sept 2024)Children through adults; immunity-focused Chinese consumersBrand predates JAT's 2018 Sunnya acquisition; relaunched in China CBEC FY2024Flagship. China online sales suspended after the adverse trademark ruling (FY2025). Sold via retail outlets in China, plus Australia and Hong Kong, where demand rose in 2Q FY26 (1H FY26 Interim Report). Inventory impairment provision A$0.66m at 30 June 2026 (FY2026 Note 8)
Neurio DHA Algae Oil Softgel and other Neurio SKUsSunnyaDHA algae oil softgels and lactoferrin powders listed in the 2018 portfolioMaternal / child2018 or earlierCurrent availability not confirmed
Moroka® Platinum Formulated Milk Powder with Lactoferrin + IgGJatcorp groupLactoferrin plus immunoglobulin G, with vitamins A, D, B6, C, E, zinc, selenium and iron (FoodNavigator-Asia)Young children to seniorsBrand launched 28 June 2023 (Shanghai CBME)Second flagship. Principal China driver in FY2025–26 under the HS/H&S incentive deed (A$11m FY26 purchase target). In about 150 Chinese mother-and-baby stores (1H FY26). Two new Moroka products launched in Q1 FY25 (Inside FMCG). Australian rollout accelerated in Q4 FY26
Moroka branded lactoferrin (stand-alone)Jatcorp groupLactoferrin product launched at the 2023 Shanghai ExpoImmunity consumers2,023Tmall flagship established in 2023
"Morokal®"Jatcorp groupReferred to in the FY2026 Appendix 4E commentary as continuing to grow in ChinaChina consumers—Possibly a variant name of Moroka; not separately described
Vietnam-specific productsJatcorp groupProducts developed specifically for Vietnam under an exclusive distribution agreementVietnamese consumersLaunch targeted before end of FY2026Vietnam revenue A$0.37m in FY2026

Own brands — specialised nutrition

Brand / productDescriptionTarget customerYearNotes
Jinvigorate Diabetic FormulaMilk formula for diabetes market; analysed by the University of Sydney; granted Low GI Symbol Certification by the Australian Glycemic Index Foundation; manufactured at ANMA (Just Food)People managing blood glucoseAnnounced c.2019–2020Morningstar lists Jinvigorate among current brands
Diabetic supplement powder and Immune supplement powder (Taiwan client)First order of over 13,000 units delivered in June 2023Taiwan market2,023Opened Taiwan market (FY2023 Appendix 4E)
iOneListed among company brands (Morningstar; Simply Wall St)——Product details not publicly disclosed
Goat milk powder-based products / children's goat milk powderANMA's first Taiwan orders were for children's goat milk powder (Just Food)Childrenc.2019–2020—
Cow milk powder, cream and skim milk powdersListed in company description (Simply Wall St)B2B / consumerOngoing—

Other and legacy brands

BrandDescriptionStatus
AbbeyardListed brand (IBISWorld)Details not disclosed
PoupinListed brand (IBISWorld)Details not disclosed
V MeatListed brand (IBISWorld); consistent with the company's "plant-based" descriptorDetails not disclosed
Cobbity CountryOats and FMCG brand developed with Shanghai Dragon (2018)Entity Cobbity Country Pty Ltd remains 100% owned; current activity not disclosed
Golden KoalaInfant formula including O-P-O premium infant formula and full-cream milk powder (2018 presentation)Entity deregistered 3 February 2026
Green Forest distributed brands (third-party, e.g. Blackmores, Swisse, a2, Aptamil, Bellamy's, Thermos, Camelbak)Daigou wholesale and distributionExited with Green Forest disposal, 9 March 2023

Services — OEM / contract manufacturing at ANMA

ServiceDescriptionNamed customers / evidenceYear
OEM powder blending and canningContract manufacturing of formulated milk powders for third-party brand ownersBTNature: up to about A$28m contract (Oct 2022); new manufacturing arrangement in 1H FY26 with initial orders received2022–2026
——Taiwan client (2023)2,023
——Two new customers in Q4 FY26, including the first customer manufacturing for sale in India; existing customers transferred orders from other manufacturers to ANMA (Q4 FY26 4C)2,026
CapacityA major production line upgrade in 1H FY26 doubled production capacity; next phase of technology and line upgrades in preparation (1H FY26 Interim Report; Q4 FY26 4C)—2025–2026

Financial Narrative

Basis of preparation and data-quality warnings

  1. FY2026 and FY2025 use the audited FY2026 Annual Report basis. This includes (a) the TPE restatement that reduced FY2025 revenue by A$3.29m and (b) the reclassification of manufacturing labour and depreciation into COGS: A$1.98m in FY2026 and A$1.94m in FY2025.

  2. FY2024 figures come from secondary summaries of the FY2024 Annual Report: continuing revenue A$52.4–52.5m, net profit A$1.6m, total assets A$25.36m, total equity A$10.83m, operating cash flow A$2.82m, and adjusted EBITDA A$3.7m. A full FY2024 income statement was not located.

  3. FY2023 uses the FY2023 Appendix 4E as reported, with A$57.37m continuing revenue including the A$20m Hong Kong trading business. The FY2024 report later appears to have re-presented FY2023 continuing revenue at about A$37m: A$52.5m is stated as +42%, implying about A$37m. The two FY2023 bases conflict.

  4. FY2022 uses the FY2023 Appendix 4E comparatives (revenue A$34.14m). The FY2022 Appendix 4E originally reported revenue of A$37.86m, before Green Forest was classified as discontinued.

  5. Pre-FY2024 per-share data are on a pre-consolidation basis (implied 1-for-30 consolidation in FY2024).

Income statement

Notes to the income statement table

  • FY2024 attributable profit of A$2.22m is implied from the movement in accumulated losses: A$81.95m at 30 June 2023 to A$79.73m at 1 July 2024. It is not a reported figure.

  • FY2024 adjusted EBITDA of +A$3.7m comes from the InvestSMART summary of the FY2025 Annual Report.

  • FY2025 adjusted EBITDA is stated as −A$1.8m in the FY2026 results commentary and −A$1.7m in the FY2025 report summary. This is a minor discrepancy.

  • D&A shown is the pre-reclassification total. After the audit reclassification, D&A in operating expenses is A$0.25m (FY2026) and A$0.32m (FY2025), with the remainder moved into COGS.

  • FY2022 and FY2023 COGS include inventory write-downs of A$3.50m and A$1.04m. FY2025 and FY2026 COGS include write-downs of A$1.46m and A$0.66m.

  • FY2026 operating expenses also include a A$0.70m loss on deconsolidation of a subsidiary.

Margins and growth (%; analyst-derived)

How the growth and margin figures are computed

  • FY2022 growth is measured against FY2021 reported revenue of A$20.96m.

  • FY2024 growth is measured against FY2023 as reported (A$57.37m). Against the re-presented FY2023 continuing base of about A$37m, FY2024 growth was about +42%.

  • FY2025 growth uses restated FY2025 revenue (A$31.55m) against A$52.45m. On the originally reported A$34.84m, the decline was about 34%.

Revenue CAGR

  • FY2022 to FY2026: 3.3% per year, using A$34.14m as the base.

  • FY2021 to FY2026: 13.2% per year, using A$20.96m as the base.

Commentary — revenue. Revenue has been volatile because the business model has changed repeatedly. FY2023's A$57.4m was inflated by the BTNature OEM contract and A$20m of Hong Kong international trading. FY2024's A$52.5m continuing revenue reflected the lactoferrin brand boom in China; China then represented over 80% of revenue according to the CEO (FoodNavigator-Asia, Sept 2024). FY2025 fell sharply on two causes: the deliberate exit from low-margin trading and the unexpected suspension of Neurio sales in China (Just Food; Inside FMCG). FY2026 recovered 23%, driven by Neurio demand in Australia and Hong Kong, Moroka in China, OEM orders and Vietnam.

Commentary — margins. On the audited basis, gross margin compressed from 19.8% to 15.8% in FY2026 despite higher revenue. Absolute gross profit was flat at about A$6.1–6.2m. The 1H FY26 gross margin was 30.0%, but that was on the pre-reclassification basis and before the FY2026 TPE netting.

The decline suggests three things:

  • second-half mix shifted towards lower-margin OEM work and Australian distributor sales;

  • TPE netting depresses reported revenue per unit;

  • inventory write-downs persisted (A$0.66m).

Commentary — profitability. Operating losses narrowed in FY2026 mainly because:

  • consultancy and professional fees fell from A$4.11m to A$2.61m as China legal spending moderated;

  • impairments normalised from A$2.64m to A$0.06m;

  • advertising fell from A$3.05m to A$2.61m.

Administration expenses rose from A$1.44m to A$1.91m.

The attributable loss nonetheless widened, from A$2.47m to A$3.49m. The FY2025 loss had been disproportionately absorbed by the 49% minority in Sunnya: the NCI share was A$4.47m of the A$6.93m loss.

Balance sheet

Notes to the balance sheet table

  • FY2024 total liabilities are derived as total assets less total equity. FY2024 owners' equity is derived from the 1 July 2024 equity balances in the FY2025/FY2026 statement of changes in equity.

  • FY2025 receivables are shown on the FY2026 presentation, which separates prepayments to suppliers (A$2.28m). The 1H FY26 report showed FY2025 current receivables of A$4.56m including supplier deposits.

  • Net debt is shown as negative when the group holds net cash.

Commentary. The balance sheet is small and lightly geared on bank debt. Borrowings are almost entirely A$1.39m of interest-free, unsecured shareholder loans with no fixed repayment terms. The A$3m bank facility (A$2m overseas bills purchased, 60-day; A$1m trade refinance, 120-day) was undrawn at reporting dates and is available until 30 July 2027 (FY2026 going-concern note).

The main balance-sheet risks are:

  • lease liabilities of A$5.17m, principally for the Derrimut premises;

  • customer prepayments of A$4.22m, which represent delivery obligations rather than cash debt;

  • erosion of total equity, which fell from A$10.83m (FY2024) to A$4.63m (FY2026).

Goodwill and intangibles are now negligible (A$0.09m) after the FY2025 write-off of Sunnya goodwill. The NCI balance has turned negative (−A$2.61m) because minority partners' share of accumulated Sunnya and LTVM losses exceeds their capital.

Cash flow

Notes to the cash flow table

  • The FY2023 cash flow statement shows "payments for PP&E" as a positive A$235,285 against PP&E additions of A$229,283. This is likely a sign-presentation error in the unaudited 4E, so the absolute value is used here.

  • FY2026 proceeds from asset disposals relate to the property held for sale, sold for A$1.10m.

  • The FY2025 share issue was A$234 on the exercise of options, shown as 0.

Commentary. Cash generation is weak and episodic. FY2024 (+A$2.82m) and FY2025 (+A$1.63m) were positive, but FY2025 was flattered by working capital. FY2026 reverted to a −A$1.36m operating outflow despite better earnings, driven by the unwinding of trade payables, which fell from A$6.99m to A$4.26m, including the settlement of Neurio refund liabilities.

Year-end cash of A$5.61m was achieved only through the A$4.13m net entitlement offer and the A$1.08m property sale. Q4 FY26 alone produced a +A$0.92m operating inflow on a much-reduced cost base (Q4 FY26 4C). The company has needed equity in three of the last five years.

Ratios (analyst-derived)

Ratios that cannot be meaningfully calculated

ROIC: not meaningful, as NOPAT is negative in four of five years.

Net debt/EBITDA and interest coverage: not meaningful, as EBITDA is negative except FY2024 adjusted. Group finance costs were A$0.32m in FY2026, of which A$0.32m is lease interest.

Cash conversion cycle (approximate)

  • FY2026: about 50 days (DSO 21 + DIO 35 − DPO 6).

  • FY2025: about 60 days (DSO 26 + DIO 69 − DPO 35).

  • Both are derived using trade payables only. They are distorted by large customer prepayments, which effectively make the working-capital cycle partly customer-financed.

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Financial Detail

Income Statement and Per-Share Data

MetricFY2022FY2023FY2024FY2025FY2026

Revenue, continuing (AUD Mn)

34.1457.3752.4531.5538.87

Cost of goods sold (AUD Mn)

30.1446.13—25.3132.72

Gross profit (AUD Mn)

4.0011.24—6.246.15

EBITDA, statutory (AUD Mn)

-7.70-3.90—-5.86-3.37

Adjusted EBITDA (AUD Mn)

-6.46-3.283.70-1.80-2.70

Depreciation & amortisation, total (AUD Mn)

1.011.02—1.091.06

EBIT, derived (AUD Mn)

-8.71-4.92—-6.95-4.43

Finance costs (AUD Mn)

1.170.19—0.360.32

Impairment losses (AUD Mn)

1.240.74—2.640.06

Profit before tax, continuing (AUD Mn)

-8.47-2.66—-7.29-4.77

Net profit after tax, total incl. discontinued (AUD Mn)

-10.01-4.611.60-6.93-4.69

Net profit attributable to owners (AUD Mn)

-6.97-4.482.22-2.47-3.49

Non-controlling interest share of result (AUD Mn)

-3.04-0.14—-4.47-1.20

Basic EPS, as reported (AUD cents)

-0.37-0.18—-2.96-3.60

Basic EPS, consolidation-adjusted ×30, derived (AUD cents)

-11.10-5.40—-2.96-3.60

Diluted EPS, as reported (AUD cents)

-0.37-0.18—-2.96-3.60

Dividends per share (AUD cents)

00000

Margin Analysis (%)

MetricFY2022FY2023FY2024FY2025FY2026

Revenue growth YoY (%)

62.968.0-8.6-39.823.2

Gross margin, audited basis (%)

11.719.6—19.815.8

Gross margin, pre-reclassification basis (%)

11.719.6—25.920.9

EBITDA margin, statutory (%)

-22.6-6.8—-18.6-8.7

Adjusted EBITDA margin (%)

-18.9-5.77.1-5.7-6.9

Net margin, total (%)

-29.3-8.03.1-22.0-12.1

Balance Sheet

MetricFY2022FY2023FY2024FY2025FY2026

Total assets (AUD Mn)

22.8026.3125.3622.6220.43

Cash and equivalents (AUD Mn)

3.863.812.472.725.61

Trade and other receivables, current (AUD Mn)

1.847.27—2.282.28

Inventories (AUD Mn)

4.954.73—4.813.12

Property, plant & equipment (AUD Mn)

5.104.85—3.623.68

Right-of-use assets (AUD Mn)

3.532.49—5.024.79

Goodwill and intangibles (AUD Mn)

2.962.71—0.090.09

Borrowings, current (AUD Mn)

1.783.17—1.391.39

Borrowings, non-current (AUD Mn)

1.600—00

Total borrowings excl. leases (AUD Mn)

3.393.17—1.391.39

Lease liabilities, total (AUD Mn)

4.032.76—5.235.17

Net debt excl. leases (AUD Mn)

-0.47-0.63—-1.32-4.22

Net debt incl. leases (AUD Mn)

3.562.13—3.910.95

Contract liabilities, customer prepayments (AUD Mn)

3.707.58—4.444.22

Total liabilities (AUD Mn)

15.3215.8714.5318.6415.80

Equity attributable to owners (AUD Mn)

6.848.288.176.087.24

Non-controlling interests (AUD Mn)

0.642.162.66-2.10-2.61

Total equity (AUD Mn)

7.4810.4410.833.984.63

Working capital, current assets less current liabilities (AUD Mn)

1.142.63—-0.080.74

Cash Flow

MetricFY2022FY2023FY2024FY2025FY2026

Operating cash flow (AUD Mn)

-2.78-0.962.821.63-1.36

Capex, payments for PP&E (AUD Mn)

1.380.24—0.420.45

Free cash flow, OCF less capex (AUD Mn)

-4.17-1.20—1.21-1.82

Proceeds from share issues, net (AUD Mn)

8.044.25004.13

Dividends paid to ordinary shareholders (AUD Mn)

00000

Dividends paid by subsidiaries to minorities (AUD Mn)

1.180—00

Share buybacks (AUD Mn)

00000

Lease principal repayments (AUD Mn)

0.420.55—0.470.50

Proceeds from asset disposals (AUD Mn)

00—01.08

Net change in cash (AUD Mn)

-2.55-0.05—0.252.89

Returns & Leverage Ratios (%) and Financial Ratios (x)

RatioFY2022FY2023FY2024FY2025FY2026

ROE, total result / average total equity (%)

-115.1-51.515.0-93.6-108.9

ROA, total result / closing total assets (%)

-43.9-17.56.3-30.7-22.9

Current ratio (x)

1.121.20—0.991.07

Debt/equity, borrowings excl. leases (x)

0.450.30—0.350.30

Debt/equity, incl. leases (x)

0.990.57—1.661.42

Asset turnover, revenue / closing assets (x)

1.502.182.071.401.90

Days inventory outstanding (days)

6037—6935

Revenue by Region

RegionFY2025FY2026

Australia (AUD Mn)

22.0830.13

China (AUD Mn)

9.197.97

New Zealand (AUD Mn)

0.290.40

Vietnam (AUD Mn)

00.37

Region Overview

RegionFY2026

Australia growth (%)

36.5

China growth (%)

-13.3

New Zealand growth (%)

41.2

Revenue by Region and Revenue by Region (%)

RegionFY2022FY2023

International revenue (AUD Mn)

8.7724.20

Domestic (Australia) revenue (AUD Mn)

25.3733.17

International share of revenue (%)

25.742.2

Observation Details

ObservationPrice (AUD)Source / date

Price at release of Q4 FY25 4C

0.37

InvestSMART, 30 Jul 2025

Price at release of FY2025 results

0.32

InvestSMART, 29 Aug 2025

Entitlement offer issue price

0.15

16 Jan 2026

Mid-2026 aggregator quotes

0.11–0.14

InvestSMART; Simply Wall St; TradingView

Latest observed

0.086

Listcorp (Iress), viewed Oct 2026

Share Price & Returns

HorizonReturn %Basis

1-year

-73

A$0.32 (29 Aug 2025) to A$0.086 (Oct 2026), analyst-derived. TradingView showed −59.7% for one year at A$0.13

Share Count (M)

MetricFY2022FY2023FY2024FY2025FY2026

Shares on issue, as reported (M)

2,141.102,497.9583.2783.27112.36

Shares, post-consolidation equivalent ÷30, derived (M)

71.3783.2783.2783.27112.36

Capital Markets

MetricJatcorp

Market capitalisation

A$9.66m

Enterprise value excl. leases

A$5.44m

Enterprise value incl. leases

A$10.61m

EV/Sales excl. leases

0.14x

EV/Sales incl. leases

0.27x

P/E

Not meaningful (loss-making)

EV/EBITDA

Not meaningful (negative EBITDA)

P/B on owners' equity (A$7.24m)

1.33x

Price / NTA (4.048c)

2.1x

Capital Instruments

InstrumentAmount (AUD Mn)Terms

Shareholder loans

1.39

Unsecured, interest-free, no fixed repayment terms

Lease liabilities, current

0.50

Due within 12 months

Lease liabilities, non-current

4.67

Leases of 3–10 years

Bank trade facilities, undrawn

3.00

A$2m 60-day plus A$1m 120-day drawings; available to 30 Jul 2027

Revolving leasing limit, undrawn

1.50

Per 1H FY26 Note 14

Analyst Conclusions

Management guidance

No numeric FY2027 guidance has been issued. Qualitative priorities from the 1H FY26 outlook and Q4 FY26 commentary are:

  • continued revenue growth through distribution partners in Southeast Asia;

  • Moroka expansion;

  • execution of the new HS exclusive China distribution model;

  • the next phase of ANMA upgrades;

  • higher-margin OEM growth;

  • targeted R&D.

The going-concern assessment relies on a cash-flow forecast assuming "project profits are met", on access to the A$3m facility, and on the ability to cut discretionary consultancy spending.

Consensus growth expectations

Not available (no analyst coverage).

Bull case

  1. Operating inflection is visible. Q4 FY26 delivered +12% revenue and +A$0.92m operating cash flow on a cost base cut across every category. If sustained, a full-year run-rate around cash breakeven is plausible on about A$40m+ revenue.

  2. OEM optionality on a doubled ANMA. New customers (including India-bound) and order transfers from rival manufacturers could raise utilisation and absorb fixed costs. The audited COGS now carries about A$2m of manufacturing labour and depreciation.

  3. Neurio IP recovery and strategic backing. A favourable trademark invalidation outcome would reopen the China CBEC channel that drove FY2024's A$52.5m revenue and A$1.6m profit. A 31% shareholder who is also the distributor has incentives to drive volume. At about 0.14–0.27x EV/Sales, the market prices in little recovery.

Bear case

  1. Structural margin problem. The audited gross margin fell to 15.8% in FY2026 even as revenue grew. At under half of Bubs' gross margin, there is little room to fund marketing, R&D and listed-company costs.

  2. Control and concentration. The top two customers account for about 74% of revenue, and HS is shareholder, exclusive distributor, TPE recipient and underwriter. Minority shareholders bear counterparty and pricing risk with limited board independence to police it.

  3. Credibility and funding risk. Successive restatements and reclassifications, persistent going-concern qualifications, and three capital raisings in five years point to continued dilution and a governance discount. The 73% one-year share price fall suggests the market already sees this.

Key catalysts and monitorables (next 12 months)

Expected timingCatalyst
Late Oct 2026Q1 FY27 Appendix 4C: is cash flow holding positive after the seasonal Q1 lull?
Around Nov 2026AGM (date not yet confirmed in sources reviewed): remuneration vote, director elections, any strategy update
OngoingNeurio China trademark invalidation rulings; Niurui/GABT compensation enforcement
OngoingQuantification of the new HS cooperation model; FY2027 volume commitments
OngoingNamed OEM contracts at ANMA; utilisation; next-phase upgrade capex
OngoingMalaysia and Indonesia distributor agreements; Vietnam sell-through
Late Feb 20271H FY27 results: audited-basis gross margin trend; going-concern status
OngoingAny new capital raising or related-party transaction requiring shareholder approval
OngoingNSW indemnity cost assessment outcome (cash recovery)

Concluding analyst verdict

Jatcorp is a sub-A$10m-capitalisation turnaround whose investment case rests on a single strategic asset and a single strategic relationship. The asset is a China-capable powder plant in Derrimut whose capacity has just been doubled. The relationship is with the HS Group, now a 31% shareholder and exclusive China distributor.

FY2026 delivered progress. Revenue grew 23% to A$38.9m, the statutory loss narrowed 32% to A$4.7m, impairments normalised and legal costs fell. The fourth quarter was cash-generative. Cash ended at A$5.6m with no interest-bearing bank debt.

The quality of that progress is questionable, however. Audited gross profit was flat at about A$6.1m and the audited gross margin fell to 15.8%. Operating cash flow for the year was negative, and the attributable loss to Jatcorp shareholders widened to A$3.5m. In the space of a month the company corrected an AASB 15 error and accepted an audit reclassification. The auditor again flagged a going-concern material uncertainty. Two customers account for roughly three-quarters of revenue, and the board has only one expressly independent director while related-party flows with the controlling distributor are growing.

On balance this is a high-risk, binary micro-cap. Upside depends on three outcomes:

  • OEM utilisation lifting margins towards the 25–30% achieved before the cost reclassification;

  • HS converting exclusivity into contracted, growing volumes;

  • Chinese courts restoring Neurio's trademark position.

Downside is continued margin dilution, further equity issuance on HS-friendly terms and minority value leakage. The valuation of about 1.3x book and 0.1–0.3x EV/Sales offers optionality, not protection.

Investors should require two consecutive cash-positive quarters on the audited cost basis, disclosure of HS contract economics and strengthened board independence before treating the turnaround as established. Until then the stock suits only speculative mandates able to absorb a total loss.

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Executive Leadership

Board of Directors

NameRoleTenureBackground / prior rolesEducation

Peng Shen

Non-Executive Chairman

Director since 20 Jun 2022; Chairman since 1 Sep 2022

Former CFO of Yancoal Australia (to 2013); Secretary and Director at China Shenhua Energy; Director of Investor Relations at CHN Energy Investment Group; former director of Carabella Resources and Wanguo Gold Group; senior auditor at Deloitte Touche Tohmatsu (MarketScreener)

University of Melbourne (graduate, 2003); Central University of Finance & Economics (undergraduate, 1998)

Dr Xinpeng (Sean) Li

Executive Director and CEO

ED since Mar 2025; acting CEO from 3 Sep 2025; CEO since 15 Sep 2025

10+ years in commercialisation, investment analysis, operations and cross-border acquisitions; senior roles at Power Construction Corporation of China (ASX announcement, 15 Sep 2025)

BEng Chemical Engineering (Northwest University); Master of Mechanical Engineering (UNSW); PhD Chemistry (UNSW)

Kieran Pryke

Non-Executive Independent Director

Appointed c.2024

More than two decades of financial expertise (Motley Fool profile)

—

Zhan (Jack) Wang

Non-Executive Director

Re-appointed 29 Oct 2025

ED from Jun 2022; MD Sep 2022 to Nov 2024; sole director of Gold Brick Capital (19.99% holder at Nov 2024); director of Pacific Healthy International Holdings and Pacific Healthy ANZ (distributors of dairy products, vitamins and cosmetics); more than a decade in cross-border e-commerce (Food & Drink Business)

—

“—” = not publicly disclosed.

Board & Management Changes

DateChange

20 Jun 2022

Peng Shen and Zhan Wang appointed

1 Sep 2022

Brett Crowley (Chair) and Bing Hui Gong removed; Zhi Guo Zhang appointed COO and ED

7–8 Sep 2022

Bo Qiang ceased as MD (resigned as NED 25 Nov 2022); Zhan Wang appointed MD

10 Jan 2023

CEO Wilton Yao terminated (litigation ongoing)

31 Jan 2023

Sunny Jian Xin Liang appointed COO and ED

8 Jan 2024

Sunny Liang appointed CEO

Nov 2024

Zhan Wang resigned as MD and director

Mar 2025

Sean Li appointed ED

3 Sep 2025

Sunny Liang resigned as CEO and ED

15 Sep 2025

Sean Li appointed CEO (3-month notice by CEO under appointment terms)

29 Oct 2025

Zhan Wang re-appointed as NED

Directors' Remuneration

ItemFY2025FY2026

Aggregate directors' fees (AUD Mn)

0.560.53

CEO Sunny Liang total compensation (AUD Mn)

0.37—

Related-party directors' remuneration and consulting fees, Q4 FY26 quarter only (AUD Mn)

—0.12

Major Shareholders

HolderStake %As atSource

HS Global E-Commerce (HK) Limited and Simon Lin (combined)

31.30

16 Jan 2026

1H FY26 Interim Report

Gold Brick Capital (Zhan Wang)

19.99—

Food & Drink Business

Superhero Securities Limited (Client A/c, nominee)

8.00

30 Jun 2023 (pre-consolidation)

Market Index

Sunny Liang (former CEO)

0.09

c.2025

Simply Wall St

Competitive Landscape

Peer Comparison FY2026

MetricJatcorpBubs Australia

Revenue

38.9111.9

Revenue growth %

23.29.2

Gross margin %

15.8 (audited basis)

39.8

EBITDA

-3.4-1.8

China revenue

8.0 (segment)

21.4

Recent Developments

Comparability caveat on quarterly figures: * Quarterly revenue in Appendix 4C reports (e.g., A$12.38m in Q2 and A$12.93m in Q4) is unaudited. It may not be on the same basis as statutory revenue after TPE netting. The four quarters cannot be reconciled to the A$38.87m annual figure from the data available.

Company Snapshot

2006

Founded

Sydney, Australia

Headquarters

SWOT Analysis

Strengths

  • Owned China-capable manufacturing: ANMA (95% owned) at Derrimut. Capacity doubled in 1H FY26, attracting OEM customers including the first India-bound customer in Q4 FY26.
  • Revenue recovery: FY2026 revenue +23% to A$38.87m. 1H FY26 +36%; Q4 FY26 +12% YoY.
  • Lower cost base: consultancy fees down from A$4.11m to A$2.61m and impairments from A$2.64m to A$0.06m in FY2026. Q4 FY26 advertising −57% and administration −19%.
  • Improved liquidity: cash of A$5.61m at 30 June 2026 (FY2025: A$2.72m). An undrawn A$3m bank facility is available to 30 July 2027.
  • Low financial debt: only A$1.39m of interest-free shareholder loans; net cash of A$4.22m excluding leases.
  • Partial legal victories: the Chongqing 2024 judgment on product legitimacy; the second-instance unfair competition win against Niurui and GABT; and indemnity costs awarded in the NSW Sunnya litigation (June 2024).
  • Customer prepayment model: A$18.94m of advance payments received in FY2026 reduces working-capital needs.

Weaknesses

  • Going-concern uncertainty: a material uncertainty paragraph has been flagged in FY2023, 1H FY26 and the FY2026 audit report.
  • Thin and declining audited gross margin: 15.8% in FY2026 versus 19.8% in FY2025, against 39.8% at Bubs.
  • Persistent losses: a net loss in four of the last five years. Accumulated losses reached A$85.68m against issued capital of A$94.81m.
  • Customer concentration: one customer provided A$23.64m (60.8%) and a second A$5.03m (12.9%) of FY2026 revenue.
  • Financial reporting quality: in FY2026 the company restated FY2025 revenue for TPE (A$3.29m) and then reclassified about A$2m of costs into COGS in the audit. FY2023 quarterly 4Cs had also been restated. Unaudited 4E figures (e.g., FY2023 capex sign) contain presentation inconsistencies.
  • Governance: one independent director out of four; four CEO/MD changes since 2022; extensive related-party dealings with HS and Pacific Healthy entities.
  • Negative operating cash flow in FY2026: −A$1.36m despite a narrower loss.

Opportunities

  • OEM growth: doubled ANMA capacity; new India-bound customer; transfers from competitor manufacturers.
  • Southeast Asia: Vietnam (A$0.37m in year one), plus Malaysia and Indonesia distributor discussions.
  • Moroka retail expansion: about 150 Chinese stores, with Australian rollout under way.
  • Neurio IP recovery in China: Sunnya is pursuing trademark invalidation. Success would reopen the CBEC channel that underpinned FY2024's A$52.5m revenue.
  • Legal cost recoveries: indemnity cost assessment in progress in NSW. A claim of up to about A$30m against defendants was flagged in FY2023, with recoverability uncertain.
  • Bolt-on M&A: management has a stated appetite for Australian health brands, now with a supportive 31% shareholder.

Threats

  • Loss of the Neurio trademark in China: online sales already suspended; refund liabilities of A$0.89m and inventory provisions of A$0.66m remained at 30 June 2026.
  • Distributor dependence and control: HS holds 31.30%, is exclusive China distributor and receives TPE and marketing fees. This creates bargaining-power and minority-shareholder risks.
  • Chinese demographic decline and regulation: falling birth rates and evolving CBEC customs and testing requirements.
  • Competitive intensity: well-capitalised peers (Bubs at A$111.9m revenue) and domestic Chinese giants adding lactoferrin.
  • Dilution risk: equity was raised in FY2022 (A$8.04m), FY2023 (A$4.25m) and FY2026 (A$4.13m). Further raisings are likely if cash burn resumes.
  • Litigation: the former CEO Wilton Yao damages claim; ongoing Chinese trademark proceedings; legal fees accrued for Neurio proceedings were A$1.34m at 31 December 2025.

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Key Developments

DateEventSignificance
Mar 2025Dr Sean Li appointed Executive DirectorFuture CEO enters board
Apr 2025Q3 FY25 quarterly; Moroka sales stronger than expected in Q3 and Q4Partially offset Neurio suspension
10 Jul 2025Registered office moved to 21 Paramount Blvd, DerrimutCost consolidation at factory
11 Jul 2025Profit warning: FY2025 net loss expected at A$7.6–8.0m. Causes cited: revenue contraction, Sunnya goodwill impairment, A$1.4m inventory write-down, and A$4.1m legal and professional feesNegative; China legal dispute costs crystallised
Jul 2025H&S reaffirmed commitment to the A$11m FY2026 Moroka purchase target (about 22% increase)Visibility on China volumes
30 Jul 2025Q4 FY25 quarterly; Q4 revenue about A$11.5m with record "618" festival salesSeasonal peak
28–29 Aug 2025FY2025 results: revenue A$34.8m as originally reported (−34%); net loss A$6.93m; adjusted EBITDA −A$1.7mWeakest year since FY2023
2 Sep 20251,000,000 shares issued under distributor Sales Incentive PlanDistributor alignment; minor dilution
3 Sep 2025CEO Sunny Liang resignedLeadership transition
15 Sep 2025Dr Sean Li appointed CEONew strategy owner
13 Oct 2025Contract to sell held-for-sale property for A$1.10mLiquidity
Oct 2025Q1 FY26 quarterly: seasonal slowdown after 618—
29 Oct 2025Zhan (Jack) Wang re-appointed NEDMajor shareholder back on board
Nov 2025CIIE Shanghai participation; prospective customers subsequently toured ANMAOEM pipeline building
24 Nov 2025Property sale settled; A$0.13m loss on disposal—
1H FY26Exclusive distribution agreement signed in VietnamNew market
1H FY26BTNature manufacturing arrangement; initial orders producedOEM revenue
1H FY26ANMA major production line upgrade doubled capacityCapacity for OEM growth
1H FY26Moroka launched into about 150 mother-and-baby stores in ChinaChannel diversification
1H FY26 (by Feb 2026)Chongqing second-instance judgment in Sunnya's favour vs Niurui and GABT (unfair competition / trade dress); defendants ordered to cease, correct and compensatePartial legal win; the separate trademark ownership dispute continues
Dec 2025A$4.2m non-renounceable entitlement offer (s708AA), fully underwritten by HS GlobalFunding
16 Jan 202628,089,785 shares issued at A$0.15; HS and Simon Lin combined stake rose to 31.30%; HS treated as related partyChange of influence; liquidity
29 Jan 2026Q2 FY26 quarterly: revenue A$12.38m (unaudited, as reported in the 4C)Strong quarter
3 Feb 2026Golden Koala Group deregisteredSimplification; A$0.70m deconsolidation loss
26 Feb 20261H FY26 results: revenue A$23.0m (+36%); NPAT −A$2.43m (63% improvement); EBITDA −A$1.71m; net current liabilities A$1.72m; going-concern emphasis paragraphImprovement but liquidity strain
30 Apr 2026Q3 FY26 quarterly releasedDetails not captured
Q4 FY26Company-run China online store operations terminated; new cooperation model with H&S as exclusive China distributorStructural change in China go-to-market
Q4 FY26ANMA won two new customers including the first India-bound OEM customer; existing customers moved orders to ANMAOEM momentum
Q4 FY26Malaysia and Indonesia distributor talks progressing; Moroka rollout in Australia acceleratedDiversification
30 Jul 2026Q4 FY26 quarterly: revenue A$12.93m (+12% YoY); operating cash inflow A$0.92m; related-party payments A$0.35m (including A$0.23m marketing fee to HS Group)Cash-positive quarter
28 Aug 2026FY2026 Appendix 4E: revenue A$38.87m (+23%); NPAT −A$4.69m; FY2025 restated for TPE (revenue −A$3.29m)Accounting error corrected
28 Aug 2026Bank facility availability disclosed as extended to 30 Jul 2027Liquidity support
22 Sep 2026Audited FY2026 Annual Report: COGS reclassification (FY2026 +A$1.98m; FY2025 +A$1.94m); no change to net loss or balance sheet; going-concern material uncertaintySecond presentation change in a month

Financial Performance

Explore key financial metrics, segmented revenue, balance sheet health, and performance trends.

Revenue

4 charts
Income Statement: Revenue & Gross Profit: Revenue, continuing rose from AUD 34.1 Mn in FY2022 to AUD 38.9 Mn in FY2026.
Jatcorp Limited — Income Statement: Revenue & Gross Profit
Series (AUD Mn)FY2022FY2023FY2024FY2025FY2026
Revenue, continuing34.157.452.531.638.9
Cost of goods sold30.146.1—25.332.7
Gross profit411.2—6.26.2

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Unlock Company Contacts

Connect with Key Decision-Makers

Access verified employee contacts and decision-maker information from this company to support your sales, lead generation, and business development efforts.